Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)

Journal of Medicinal Chemistry

Volumn 45, Issue 17, 2002, Pages 3721-3738

  Widler, Leo ^a   Jaeggi, Knut A ^a   Glatt, Markus ^a   Müller, Klaus ^a   Bachmann, Rolf ^a   Bisping, Michael ^a   Born, Anne Ruth ^a   Cortesi, Reto ^a   Guiglia, Gabriela ^a   Jeker, Heidi ^a   Klein, Rémy ^a   Ramseier, Ueli ^a   Schmid, Johann ^a   Schreiber, Gerard ^a   Seltenmeyer, Yves ^a   Green, Jonathan R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE MINERALIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HYPERCALCEMIA; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE RESORPTION; CALCITRIOL; DIPHOSPHONATES; HYPERCALCEMIA; IMIDAZOLES; KIDNEY; MICE; PARATHYROIDECTOMY; RATS; SKULL; STRUCTURE-ACTIVITY RELATIONSHIP; THYROIDECTOMY;

EID: 0037103322     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020819i     Document Type: Article

References (88)

1. On the action of acetyl chloride on phosphorus acid
2. History of the bisphosphonates: Discovery and history of the non-medical uses of bisphosphonates
3. Effects of pyrophosphate on hydroxyapatite and its implications in calcium homeostatis
4. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo
5. From polyphosphates to bisphosphonates and their role in bone and calcium metabolism
6. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
7. Bisphosphonates: Mechanisms of action
8. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo
9. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
10. Molecular mechanisms of action of bisphosphonates
11. The pharmacology of bisphosphonates and new insights into their mechanisms of action
12. Bisphosphonates: From the laboratory to the clinic and back again
13. Bisphosphonates: Pharmacology, mechanism of action and clinical uses
14. The bisphosphonate odyssey. A Journey from chemistry to the clinic
15. Mechanisms of action of bisphosphonates
16. Overview of bisphosphonates
17. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
18. Bisphosponates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
19. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
20. Interaction between effects of parathyroid hormone and bisphosphonates on regulation of osteoclast activity by the osteoblast-like cell line UMR-106
21. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
22. Bisphosphonates in development for metabolic bone disease
23. Drugs in development for the treatment of metabolic bone disease
24. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-2-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats
25. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone
26. Alendronate and osteoporosis
27. Alendronate: An update of its use in osteoporosis
28. Review of risedronate in the treatment of osteoporosis
29. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease
30. Ibandronate
31. Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats
32. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats
33. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis
34. Amino-substituted gem-bisphosphonates
35. Structure-activity relationships of various bisphosphonates
36. Bisphosphonates: Structure-activity relationship and therapeutic implications
37. Designing drugs for stronger bones
38. Bisphosphonate therapy in acute and chronic bone loss: Physical chemical considerations in bisphosphonate-related therapies
39. Mechanisms of action of etidronate and other bisphosphonates
40. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships
41. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group
42. The design and synthesis of boneactive phosphinic acid analogs. I. The (pyridylamino)phosphonoalkylphosphinates
43. Bisphosphonate antiresorptive structure-activity relationships
44. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity
45. Binding and antiresorptive properties of heterocyclecontaining bisphosphonate analogs: Structure-activity relationships
46. Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activites of aminomethylenebisphosphonate derivatives
47. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives
48. Structure-activity relationship of histamine analogs, 2: Esters of 4-(hydroxymethyl)imidazoleacetic acid
49. An improved preparation of imidazole-4(5)-methanol hydrochloride
50. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
51. The pyhsicochemical interaction of a bisphosphonate (BP), a conformationally restricted BP, and a phosphonoalkylphosphinate (PAP), with bone minerals
52. The phsphonate moieties of bisphosphonates are more than just a targeting function: Evidence from the study of bisphosphonate analogues in vitro
53. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat
54. Effects of short-term treatment with the bisphosphonate zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the candellous bone formed before, during, and after treatment
55. Renal tolerability profile of novel, potent bisphosphonates in 2 short-term rat models
56. The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo
57. Characterization of the early ultrastructural and biochemical events occurring in dichloromethane diphosphonate nephrotoxicity
58. Nephrotoxicity screening in rats: A validation study
59. Nephrotoxicity screening in rats: General approach and establishment of test criteria
60. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat
61. Zoledronate (CGP 42′446), a bisphosphonate protects against metaphyseal intracortical defects in experimental inflammatory arthritis
62. Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate)
63. Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties and biochemical markers in the ovariectomized rat
64. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
65. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
66. Visualisation of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
67. A dose-finding study of zoledronate in hypercalcemic cancer patients
68. Single infusion of zoledronate in Paget's disease of bone: A placebo controlled, dose-ranging study
69. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized doseresponse study
70. A single annual injection of the bisphosphonate, zoledronic acid, stably reduces bone turnover and increases bone density in postmenopausal osteoporosis
71. Intravenous zoledronic acid in postmenopausal women with low bone mineral density
72. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
73. A procedure for detecting phosphonolipids on thin-layer chromatograms
74. The reaction of cyanamide with (α-amino-acetals and α-amino-aldehydes
75. Amidines and related compounds. 6. Studies on structureactivity relationships of antihypertensive and antisecretory agents related to clonidine
76. Ueber 1,2,4-thiadiazoles. I. Preparation and amino1,2,4-thiadiazoles
77. Studies on imidazole compounds. I. A synthesis of imidazoles with functional groups in the 2-position
78. Conjugate addition-decarboxylation of magnesium monoethyl malonate to enones: A convenient one-flask addition of acetate
79. Thiazolylmethylenetriphenylphosphorane and its benzo derivative: Stable and practical Wittig reagents for the synthesis of vinylthiazoles and vinylbenzothiazoles. Two-carbon homologation of aldehydes
80. Synthesis and properties of 5-membered heterocyclic disulfides: Application for enzyme modification